• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Cemax-Icon awaits rebound of IPO market

Article

PACS software developer Cemax-Icon is laying plans to launch itslong-awaited initial public offering as soon as the IPO marketregains its footing. Executives with the Fremont, CA, companysay they should be able to launch the offering within five daysof

PACS software developer Cemax-Icon is laying plans to launch itslong-awaited initial public offering as soon as the IPO marketregains its footing. Executives with the Fremont, CA, companysay they should be able to launch the offering within five daysof getting the go-ahead from their investment advisors.

Cemax-Icon officials confirmed earlier this year that they werelaying plans for an IPO (SCAN 6/19/96). Their moves are beingclosely watched, as a public Cemax-Icon would give investors apure play on the promising PACS segment of medical imaging.

Cemax-Icon has put the finishing touches on the appropriate paperworkrequired by the Securities and Exchange Commission to issue theIPO, according to president and CEO Terry Ross. The company iswaiting for the IPO market to improve before going forward, whichmay happen by mid-September, he said.

Ross hopes to raise $22 million after expenses by issuing 2.8million shares on the NASDAQ exchange, priced between $8 and $10a share. The funds would be used for general corporate purposes.

Would-be investors might be attracted to Cemax-Icon by the company'sstrong revenue growth, which has risen at an annual rate of 40%in the past five years. Cemax-Icon expects to post sales of $26million this year, according to the offering's prospectus.

Cemax-Icon also has an impressive stable of OEM partners, withToshiba, Imation (formerly 3M), and Lucent Technologies (formerlyAT&T) accounting for about 45% of revenues. The vendor's backlogstands at a company record $11.5 million.

On the downside, Cemax-Icon has yet to turn a profit. The companyestimates that current operating funds, along with IPO proceeds,will be enough to fund operations at least through 1997, accordingto the prospectus.

Recent Videos
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Related Content
© 2024 MJH Life Sciences

All rights reserved.